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Abstract 
Primary  cardiac  lymphoma  is  extremely
uncommon. We report a case of a 54 year old
Caucasian  male  with  a  history  of  non-small
cell lung cancer treated by surgical resection
who presented with chest pain and dyspnea on
exertion.  Computerized  tomography  (CT)
imaging confirmed a 7.8ﾥ3.8 cm right atrial
soft tissue mass infiltrating the lateral wall of
the right atrium, and a 5 cm pericardiophrenic
mass. Echocardiography confirmed a moderate
pericardial effusion without tamponade physi-
ology. Percutaneous biopsy of the pericardio-
phrenic  mass  revealed  pathologic  features
diagnostic of NK/T-cell lymphoma. He received
CHOP chemotherapy with some improvement
in  symptoms,  but  experienced  radiographic
progression after 2 cycles. He received pallia-
tive involved field radiotherapy but developed
new  sites  of  progressive  disease  within  the
abdomen  and  died  shortly  after  completing
radiotherapy. NK/T-cell lymphomas are aggres-
sive  tumors  that  may  present  with  unusual
extranodal  disease  sites.  Prompt  diagnosis
with consideration for referral to a specialty
center with experience in treatment of these
rare tumors may offer the greatest potential for
improving treatment outcomes.
Introduction
NK/T-cell  lymphomas  (NKTCLs)  represent
an uncommon subtype of non-Hodgkin’s lym-
phoma  (NHL),  comprising  only  5%  of  NHL
cases  in  Western  countries.1-2 NKTCLs  are
highly aggressive, accounting for their previ-
ous description as lethal midline granulomas.
NKTCLs generally have poor outcomes, with
high rates of relapse and progression even in
the setting of limited stage disease.1,3 At least
80% of NKTCLs are localized at presentation,
most commonly to the nasal cavity with exten-
sion to the nasopharynx and paranasal sinus-
es.3 However, distant sites of involvement may
be  observed,  most  commonly  involving  the
skin,  liver,  lung,  gastrointestinal  tract,  or
testis.1 In  cases  of  extranodal  NKTCLs,  only
rare reports exist of primary cardiac involve-
ment.4-6 We report a rare case of a patient with
extranodal  NKTCL  presenting  with  primary
cardiac involvement. 
Case Report
A 54 year old Caucasian male with a history
of polysubstance abuse and stage IA squamous
cell lung carcinoma resected 2 years previous-
ly, presented to clinic with a 3 month history of
progressive chest pain and dyspnea on exer-
tion.  Physical  examination  revealed  normal
vital signs and no abnormalities on cardiopul-
monary examination. Chest x-ray revealed a
new  mass  in  the  anterior  left  lower  medi-
astinum.  Computerized  tomography  (CT)
imaging  of  the  chest  showed  a  7.8ﾥ3.8  cm
right atrial soft tissue mass infiltrating the lat-
eral wall of the right atrium with associated
pericardial  effusion,  and  a  5  cm  pericardio-
phrenic mass, both new when compared to CT
imaging  performed  6  months  previously
(Figure  1).  Transthoracic  echocardiography
showed  a  large  irregular,  mural  right  atrial
mass in the area of the tricuspid annulus with
extensive infiltration of both ventricles and the
posterior wall of the left atrium. In addition, he
was noted to have a pericardial effusion with
early  tamponade  physiology.  A  percutaneous
core  needle  biopsy  of  the  pericardiophrenic
mass was performed (Figure 2). Hematoxylin
and eosin stained sections of the mediastinal
mass revealed a dense infiltrate of primarily
small lymphocytes with irregular nuclear con-
tours  in  a  background  of  focal  fibrosis  and
scattered  histiocytes.  Immuno  histochemistry
and  in  situ  hybridization demonstrated  that
the neoplastic cells co-expressed CD3ʵ, CD56,
Epstein-Barr virus encoded RNA, granzyme-B,
and TIA-1. Mitotic figures were easily found,
but  angiodestruction  was  not  present.  The
final  pathologic  diagnosis  was  extranodal
NK/T-cell lymphoma, nasal-type. 
A  unilateral  bone  marrow  biopsy  did  not
show  any  morphologic  evidence  of  involve-
ment  by  lymphoma.  Flow  cytometry  on  the
bone  marrow  biopsy  was  negative  and
immunostaining  for  EBER  was  negative.
Retrospective review of his non-small cell lung
cancer biopsy confirmed squamous carcinoma
with no atypical findings, and EBER immunos-
taining was negative. His blood counts at diag-
nosis were normal, including a normal LDH of
160  U/L.  HIV  testing  was  negative.  Nasal
endoscopy with biopsies and CT/PET imaging
were recommended in order to complete the
staging  evaluation.  Multiple  attempts  were
made  to  schedule  and  perform  these  proce-
dures,  but  the  patient  was  unwilling  and/or
unable to comply due to his chaotic psychoso-
cial  circumstances  and  his  concerns  about
costs due to lack of medical insurance. 
Although  a  more  dose-intensive  regimen
would have been preferred, CHOP chemother-
apy was administered for palliative treatment
in this case due to issues with poor patient
compliance  and  continued  polysubstance
abuse. Two attempts had been made to admin-
ister the more dose-intensive SMILE (steroids,
methotrexate,  ifosfamide,  L-asaparaginase,
and etoposide) regimen as an inpatient, but
the patient left within several hours of admis-
sion against medical advice. There were sever-
al  intervening  emergency  department  visits
with tachyarrhythmias and cocaine intoxicia-
tion.  Based  on  these  limiting  factors,  the
patient received 2 cycles of CHOP chemothera-
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Figure 1. Computerized tomography imag-
ing confirms a large left pericardiac mass
(top right arrow) and infiltrative mass aris-
ing from the right atrium (left arrow).[Hematology Reports 2011; 3:e9]
py as an outpatient, but demonstrated disease
progression  on  follow  up  CT  imaging.  The
patient was then referred for palliative radio-
therapy which he tolerated well with improved
symptoms of chest pain and dyspnea. He devel-
oped  acute  abdominal  pain  approximately  1
week  after  completing  radiotherapy,  and
repeat CT imaging showing a new confluent
soft tissue mass encasing the duodenum, pan-
creatic head, and inferior vena cava. He died
from progressive lymphoma within 2 weeks of
completing palliative radiotherapy.
Discussion
Although  improved  outcomes  have  been
reported  with  combined  chemoradiation  for
treatment of limited stage nasal NK/T-cell lym-
phoma,7-8 outcomes remain poor for dissemi-
nated disease and extranasal NKTCLs. Given
the rarity of primary cardiac lymphomas, most
clinical management decisions of this entity
are extrapolated from experience with other
aggressive  lymphoma  subtypes  presenting
with  advanced  stage  disease  and  extranodal
involvement.9
Chemotherapy resistance of NKTCLs may be
related to high rates of expression of P-glyco-
protein, which is the product of the multidrug
resistance  (MDR)  1  gene.10 High-intensive
chemotherapy regimens combined with radio-
therapy may be a rationale means for bypass-
ing the innate MDR of NKTCLs, with some lim-
ited data to support improved outcomes with
such an approach.1,11
L-asparaginase has shown impressive sin-
gle-agent  activity  in  NKTCLs.12 More  recent
reports have focused on combining L-asparag-
inase with chemotherapy agents known to be
independent of MDR. For example, outcomes
with the SMILE regimen, have reported rates
of response exceeding 50% in a phase I study
of relapsed, refractory NKTCLs.13 These prom-
ising results have led to on ongoing phase II
study of SMILE chemotherapy in Asia. 
Although prognosis remains poor in dissem-
inated NKTCLs, prompt diagnosis and possible
referral to a specialty center with experience
in treatment of NKTCLs may offer patients the
best opportunity for longer-term disease out-
comes.
References
1. Kohrt  H,  Advani  R.  Extranodal  natural
killer/t-cell lymphoma: Current concepts in
biology  and  treatment.  Leuk  Lymphoma
2009;50:1773-84.
2. Au  WY,  Weisenburger  DD,  Intragumto  -
rnchai  T,  et  al.  Clinical  differences
between  nasal  and  extranasal  natural
killer/t-cell lymphoma: A study of 136 cases
from  the  international  peripheral  t-cell
lymphoma project. Blood 2009;113:3931-7.
3. Cheung MM, Chan JK, Wong KF. Natural
killer cell neoplasms: A distinctive group of
highly  aggressive  lymphomas/leukemias.
Semin Hematol 2003;40:221-32.
4. Fernandes  F,  Soufen  HN,  Ianni  BM,
Arteaga E, Ramires FJ, Mady C: Primary
neoplasms of the heart. Clinical and histo-
logical presentation of 50 cases. Arq Bras
Cardiol 2001;76:231-7.
5. Lam KY, Dickens P, Chan AC. Tumors of
the  heart.  A  20-year  experience  with  a
review  of  12,485  consecutive  autopsies.
Arch Pathol Lab Med 1993;117:1027-31.
6. Bagwan  IN,  Desai  S,  Wotherspoon  A,
Sheppard  MN.  Unusual  presentation  of
primary  cardiac  lymphoma.  Interact
Cardiovasc Thorac Surg 2009;9:127-9.
7. Kim SJ, Kim K, Kim BS, et al. Phase ii trial
of  concurrent  radiation  and  weekly  cis-
platin  followed  by  vipd  chemotherapy  in
newly  diagnosed,  stage  ie  to  iie,  nasal,
extranodal  nk/t-cell  lymphoma:  Consor  -
tium for improving survival of lymphoma
study. J Clin Oncol 2009;27:6027-32.
8. Yamaguchi M, Tobinai K, Oguchi M, et al.
Phase i/ii study of concurrent chemoradio-
therapy for localized nasal natural killer/t-
cell  lymphoma:  Japan  clinical  oncology
group study jcog0211. J Clin Oncol 2009;
27:5594-600.
9. Anghel G, Zoli V, Petti N, et al. Primary car-
diac lymphoma: Report of two cases occur-
ring in immunocompetent subjects. Leuk
Lymphoma 2004;45:781-8.
10. Yamaguchi  M,  Kita  K,  Miwa  H,  et  al.
Frequent  expression  of  p-glycoprotein/
mdr1  by  nasal  t-cell  lymphoma  cells.
Cancer 1995;76:2351-6.
11. Aviles A, Cleto S, Castaneda C, Nambo MJ.
Cmed  in  the  treatment  of  nasal  natural
killer cell lymphoma with distant metas-
tases. Hematology 2007;12:241-4.
12. Jaccard  A,  Petit  B,  Girault  S,  et  al.  L-
asparaginase-based treatment of 15 west-
ern patients with extranodal nk/t-cell lym-
phoma and leukemia and a review of the
literature. Ann Oncol 2009;20:110-6.
13. Yamaguchi M, Suzuki R, Kwong YL, et al.
Phase  i  study  of  dexamethasone,
methotrexate, ifosfamide, l-asparaginase,
and  etoposide  (smile)  chemotherapy  for
advanced-stage,  relapsed  or  refractory
extranodal  natural  killer  (nk)/t-cell  lym-




Figure 2. Extranodal NK/T-cell lymphoma, nasal type. Hematoxylin and eosin stained
sections of the mediastinal mass reveals a dense infiltrate of primarily small lymphocytes
with irregular nuclear contours (A) and immunohistochemistry shows the neoplastic cell
co-express CD3ʵ (B) and CD56 (C). Almost all of the neoplastic cells contained EBV-
encoded RNA (EBER) when assessed by in situ hybridization. 